Retinoblastoma protein-interacting zinc finger 1, a tumor suppressor, augments lipopolysaccharide-induced proinflammatory cytokine production via enhancing nuclear factor-κB activation

Cellular Immunology

Volumn 264, Issue 2, 2010, Pages 114-118

  Noman, Abu Shadat Mohammod ^a   Koide, Naoki ^a   Iftakhar E Khuda, Imtiaz ^a   Dagvadorj, Jargalsaikhan ^a   Tumurkhuu, Gantsetseg ^a   Naiki, Yoshikazu ^a   Komatsu, Takayuki ^a   Yoshida, Tomoaki ^a   Yokochi, Takashi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

LPS; NF B; P53; Retinoblastoma protein interacting zinc finger 1; RIZ1

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN INTERACTING ZINC FINGER 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; HISTONE LYSINE METHYLTRANSFERASE; LIPOPOLYSACCHARIDE; PRDM2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CELL LINE; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MOLECULAR CLONING; MUTATION; PATHOLOGY; SECRETION (PROCESS); TRANSCRIPTION INITIATION;

ANIMALS; CELL LINE; CLONING, MOLECULAR; HISTONE-LYSINE N-METHYLTRANSFERASE; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MUTATION; NF-KAPPA B; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955096671     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.05.007     Document Type: Article

References (38)

1. He L., Yu J.X., Liu L., Buyse I.M., Wang M.S., Yang Q.C., Nakagawara A., Brodeur G.M., Shi Y.E., Huang S. RIZ1, but not the alternative RIZ2 product of the same gene, is under expressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 1998, 58:4238-4244.
2. Jiang G., Liu L., Buyse I.M., Simon D., Huang S. Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int. J. Cancer 1999, 83:541-546.
3. Chadwick R.B., Jiang G.L., Bennington G.A., Yuan B., Johnson C.K., Stevens M.W., Niemann T.H., Peltomaki P., Huang S., De la Chapelle A. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA 2000, 97:2662-2667.
4. Sasaki O., Meguro K., Tohmiya Y., Funato T., Shibahara S., Sasaki T. Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia. Br. J. Haematol. 2002, 119:940-948.
5. Poetsch M., Dittberner T., Woenckhaus C. Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. Oncogene 2002, 21:3038-3042.
6. Du Y., Jenkins N.A., Copeland N.G. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 2005, 106:3932-3939.
7. Carling T., Kim K.C., Yang X.H., Gu J., Zhang X.K., Huang S. A histone methyltransferase is required for maximal response to female sex hormones. Mol. Cell Biol. 2004, 24:7032-7042.
8. Du Y., Carling T., Fang W., Piao Z., Sheu J.C., Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 2001, 61:8094-8099.
9. Snoeks L., Weber C.R., Turner J.R., Bhattacharyya M., Wasland K., Savkovic S.D. Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells. Infect. Immun. 2008, 76:4677-4685.
10. Lim J.H., Jono H., Koga T., Woo C.H., Ishinaga H., Bourne P., Xu H., Ha U.H., Xu H., Li J.D. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS ONE 2007, 2:e1032.
11. I.I. Khuda, N. Koide, A.S. Noman, J. Dagvadorj, G. Tumurkhuu, Y. Naiki, T. Komatsu, T. Yoshida, T. Yokochi, Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and augments TLR4 signaling, Immunology, in press.
12. Kawai T., Akira S., signaling T.L.R. Cell Death Differ. 2006, 13:816-825.
13. West A.P., Koblansky A.A., Ghosh S. Recognition and signaling by toll-like receptors. Annu. Rev. Cell Dev. Biol. 2006, 22:409-437.
14. Kawai T., Adachi O., Ogawa T., Takeda K., Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11:115-122.
15. Horng T., Barton G.M., Medzhitov R. TIRAP: an adapter molecule in the toll signaling pathway. Nat. Immunol. 2001, 2:835-841.
16. A.S. Noman, N. Koide, F. Hassan, I.I. Khuda, J. Dagvadorj, G. Tumurkhuu, S. Islam, Y. Naiki, T. Komatsu, T. Yoshida, T. Yokochi, Retinoblastoma protein-interacting zinc finger 1 (RIZ1) regulates malignancy of monocytic leukemia cells via activation of p53, Caner Invest., submitted for publication.
17. Wati S., Li P., Burrell C.J., Carr J.M. Dengue Virus (DV) replication in monocyte-derived macrophages is not affected by tumor necrosis factor alpha (TNF-α), and DV infection induces altered responsiveness to TNF-α stimulation. J. Virol. 2007, 81:10161-10171.
18. Liu J., Jones K.L., Sumer H., Verma P.J. Stable transgene expression in human embryonic stem cells after simple chemical transfection. Mol. Reprod. Dev. 2009, 76:580-586.
19. Hassan F., Islam S., Tumurkhuu G., Naiki Y., Koide N., Mori I., Yoshida T., Yokochi T. Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer 2006, 6:281.
20. Chakravortty D., Kato Y., Sugiyama T., Koide N., Mu M.M., Yoshida T., Yokochi T. The inhibitory action of sodium arsenite on lipopolysaccharide-induced nitric oxide production in RAW 267.4 macrophage cells: a role of Raf-1 in lipopolysaccharide signaling. J. Immunol. 2001, 166:2011-2017.
21. Laird M.H., Rhee S.H., Perkins D.J., Medvedev A.E., Piao W., Fenton M.J., Vogel S.N. TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J. Leukoc. Biol. 2009, 85:966-977.
22. Zakut-Houri R., Oren M., Bienz B., Lavie V., Hazum S., Givol D. A single gene and a pseudogene for the cellular tumour antigen p53. Nature 1983, 306:594-597.
23. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 1999, 19:3485-3495.
24. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
25. Geng Y., Zhang B., Lotz M. Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J. Immunol. 1993, 151:6692-7000.
26. Ojaniemi M., Glumoff V., Harju K., Liljeroos M., Vuori K., Hallman M. Phosphatidylinositol 3-kinase is involved in toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur. J. Immunol. 2003, 33:597-605.
27. Matsushita K., Takeuchi O., Standley D.M., Kumagai Y., Kawagoe T., Miyake T., Satoh T., Kato H., Tsujimura T., Nakamura H., Akira S. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009, 458:1185-1190.
28. Komarova E.A., Krivokrysenko V., Wang K., Neznanov N., Chernov M.V., Komarov P.G., Brennan M.L., Golovkina T.V., Rokhlin O.W., Kuprash D.V., Nedospasov S.A., Hazen S.L., Feinstein E., Gudkov A.V. P53 is a suppressor of inflammatory response in mice. FASEB J. 2005, 19:1030-1032.
29. Liu G., Park Y.J., Tsuruta Y., Lorne E., Abraham E. P53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J. Immunol. 2009, 182:5063-5071.
30. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
31. Clevers H. At the crossroads of inflammation and cancer. Cell 2004, 118:671-674.
32. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004, 30:193-204.
33. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85.
34. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J., Baldwin A.S., Mayo M.W. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell Biol. 2000, 20:1626-1638.
35. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 2009, 9:351-369.
36. Kelly N.M., Cross A.S. Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice. FEMS Microbiol. Immunol. 1992, 4:317-322.
37. Simpson S.Q., Casey L.C. Role of tumor necrosis factor in sepsis and acute lung injury. Crit. Care Clin. 1989, 5:27-47.
38. Zentella A., Manogue K., Cerami A. The role of cachectin/TNF and other cytokines in sepsis. Prog. Clin. Biol. Res. 1991, 367:9-24.